Inclusion criteria: <br>Patients who meet the following criteria at screening will be eligible to participate in the study:<br>1. Able to understand and comply with study procedures and give written informed consent<br>2. Aged>=18 years<br>3. Have no clinically significant abnormal findings on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and clinical laboratory profiles of both blood and urine that would impair participation or safety in the trial or clinically relevant abnormal findings that in the opinion of the investigator could interfere with the objectives of the study or the safety of the patient<br>4. After treatment with stable statin therapy for at least 12 weeks prior to screening, have a screening LDL-C of no more than 10 mg/dL (0.259 mmol/L) above the NCEP ATP III target (see Note 2 below):<br>? - LDL-C<70 mg/dL (1.81 mmol/L) or <100 mg/dL (2.59 mmol/L) for patients with coronary heart disease (CHD) or CHD equivalent<br>? - LDL-C<130 mg/dL (3.36 mmol/L) for patients with multiple risk factors<br>? - LDL-C<160 mg/dL (4.14 mmol/L) for patients with 0-1 risk factor<br>Note 1: Any statin approved by the regulatory authority in the respective country is allowed, with the exception of pravastatin, lovastatin, and fluvastatin<br>Note 2: If LDL-C is greater than 10 mg/dL (0.259 mmol/L) above target, patients are only eligible for the study if they are on the maximum allowable statin dose as per approved SPC in the respective country or on the maximum dose tolerated by the respective patient.<br>5. Fasting TG value at screening is>=175 mg/dL (1.97 mmol/L) and<=500 mg/dL (5.65 mmol/L) Note: If the patient fails to meet this criterion at Screening Visit (SV) 1, a fasting re-test of TG will be allowed at a second SV<br>6. HDL-C value at screening is<=50 mg/dL (1.30 mmol/L) for men and<=55 mg/dL (1.43 mmol/L)for women<br>7. Women may be enrolled if all 3 of the following criteria are met:<br>? They are not pregnant<br>? They are not breastfeeding and<br>? They do not plan on becoming pregnant during the study<br>8. Women of childbearing potential must have a negative urine pregnancy test at screening. Women are not considered to be of childbearing potential if they meet 1 of the following criteria as documented by the investigator:<br>? - They have had a hysterectomy or tubal ligation at minimum 1 cycle prior to signing the Informed Consent Form<br>? - They are post-menopausal, defined as >=1 year since their last menstrual period for women >= 55 years of age or >=1 year since their last menstrual period and have a follicle-stimulating hormone (FSH) level in menopausal range (defined as > 40 miU/mL) for women < 55 years of age<br>9. Women of childbearing potential must agree to use an effective method of contraception from screening to the end of the study. Effective methods of contraception are those contraceptive methods with a Pearl index of <1 used consistently and correctly (including implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives or intrauterine devices)<br>10. Male study participants will be required to use condoms with a spermicide during sexual intercourse from screening to the end of the study, even if their sexual partner is or may be pregnant<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 373<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 373<br>